Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study | Zendy

Paolo Denti | Zendy; Roeland E. Wasmann | Zendy; Annelies Van Rie | Zendy; Jana Winckler | Zendy; Adrie Bekker | Zendy; Helena Rabie | Zendy; Anneke C. Hesseling | Zendy; Louvina E. van der Laan | Zendy; Carmen González-Martínez | Zendy; Heather J. Zar | Zendy; Geraint Davies | Zendy; Lubbe Wiesner | Zendy; Elin M. Svensson | Zendy; Helen McIlleron | Zendy

Open Access

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Author(s) -

Paolo Denti,

Roeland E. Wasmann,

Annelies Van Rie,

Jana Winckler,

Adrie Bekker,

Helena Rabie,

Anneke C. Hesseling,

Louvina E. van der Laan,

Carmen González-Martínez,

Heather J. Zar,

Geraint Davies,

Lubbe Wiesner,

Elin M. Svensson,

Helen McIlleron

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab908

Subject(s) - pyrazinamide , medicine , isoniazid , rifampicin , dosing , fixed dose combination , pharmacokinetics , pharmacology , tuberculosis , population , pathology , environmental health

In 2010, the World Health Organization (WHO) revised dosing guidelines for treatment of childhood tuberculosis. Our aim was to investigate first-line antituberculosis drug exposures under these guidelines, explore dose optimization using the current dispersible fixed-dose combination (FDC) tablet of rifampicin/isoniazid/pyrazinamide; 75/50/150 mg, and suggest a new FDC with revised weight bands.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research